Talk:Omecamtiv mecarbil

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Omecamtiv mecarbil.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Tip: Anchors are case-sensitive in most browsers.

This article links to one or more target anchors that no longer exist.

[[Heart failure#Systolic dysfunction|systolic heart failure]] The anchor (#Systolic dysfunction) is no longer available because it was deleted by a user before.

Please help fix the broken anchors. You can remove this template after fixing the problems. | Reporting errors

Intro[edit]

Made some changes to the intro. The extensive detail on systolic heart failure, while enlightening, is not necessary here and should be left to that subject's page. Also there are unsubstantiated claims, such as how inotropes are palliative and not curative (not even sure what that means in this context, or how omecamtiv is curative, which this claim implies), that omecamtiv offers a long term solution, and that heart failure is malignant. Also, omecamtiv mecarbil is not a brand name and thus shouldn't be capitalized. — Preceding unsigned comment added by 167.246.60.1 (talk) 17:50, 3 November 2015 (UTC)[reply]